Pluriomics BV collaborates with Multi Channel Systems to expand its Cardiovascular screening capabilities and its drug discovery services portfolio
Leiden, The Netherlands, 24th May, 2017
Pluriomics and Multi Channel Systems (MCS) today announced a collaboration to work together on cardiac safety solutions and technology demonstration. This collaboration will give Pluriomics access to Multi Channel Systems’ new 1152 electrode 96 well MEA system which will expand Pluriomics’ cardiovascular drug screening services.
Pluriomics is a leading expert in human cardiovascular stem cell technology, disease modeling and cell-based assay products and services for cardiovascular drug discovery with the mission to contribute to the efficiency of the drug discovery and development process by reducing the development length, costs and late stage attrition of novel drug candidates. Pluriomics proprietary fully functional human iPSC-derived cardiomyocytes (Pluricyte) exhibit unique electrophysiological characteristics that make them exceptionally well-suited for disease modeling and phenotypic screening.
Among their unique characteristic Pluricyte® Cardiomyocytes present well-pronounced depolarization and repolarization peaks allowing an easy detection of electrophysiological parameters (e.g. depolarization/repolarization peak amplitudes, beat rate, field potential duration) that facilitate efficient data analysis and interpretation of studies performed with MEA systems and make them especially suitable for MEA based safety and drug efficacy screenings. Pluriomics already offers services using two different MEA platforms. The Multi Channel Systems Multiwell 96 well MEA System will be the third Pluriomics’ in house platform to enable detailed electrophysiological detection of potential cardiotoxic/pro-arrhythmic effects of compounds in a 96-well plate format.
As a first step of the collaboration Pluriomics and Multi Channel Systems will organize a Workshop on June 6, 2017 welcoming partners for Multi Channel Systems Multiwell 96 well MEA System technical presentation and live demo.
Celine Hechard, VP Business Development and Marketing of Pluriomics BV, commented: “We envision this relationship will help us to expedite development of new assays on the Multi Channel Systems platform in response to customer needs. We anticipate that our relationship with MCS and development of experience with the platform will further serve our goal of becoming the first choice in the industry for drug discovery solutions in the cardiomyocyte space.”
For more information please contact:
+31 (0)71 332 2230
Pluriomics, a leading expert in human cardiovascular stem cell technology, manufactures fully functional human induced pluripotent stem cell derived cardiomyocytes (Pluricyte® Cardiomyocytes) using well-defined, serum-free medium that enhances the maturation and function of the cells. Pluriomics’ Pluricyte® Cardiomyocytes and innovative technologies are exceptionally well suited for implementation in various stages of drug discovery to improve decision-making, reduce attrition rates and provide an alternative for animal testing.
Pluriomics offers unique cardiac drug discovery and safety assessment solutions based on its best-in-class human iPSC-derived cardiomyocyte cellular assays. The company aims to contribute to the efficiency of the drug discovery and development process by delivering products and services for early discovery and safety assessment.
The company is backed by private investors, Venture Funds and strategic investment from regional investment funds (Vesalius Biocapital, InnovationQuarter, S.R.I.W, SFPI-FPIM, Sambrinvest).
Pluriomics is based in Leiden, The Netherlands and in Gosselies, Belgium.
For more information please visit www.pluriomics.com
To view this press release as a PDF file, click here